AI Article Synopsis
- Immunotherapy, specifically ipilimumab, is a common treatment for metastatic melanoma, but finding reliable biomarkers to predict patient response remains a challenge, risking severe side effects.* -
- A study showed that patients with a higher Body Mass Index (BMI) had significantly better responses to ipilimumab, as well as a lower likelihood of brain metastases compared to those with normal BMI.* -
- While patients with a higher BMI tended to have longer overall survival rates, there were no significant differences in gender, T-stage, side effects, or progression-free survival between the BMI groups.*
Article Abstract
Introduction: Immunotherapy is a well-established treatment option in patients with metastatic melanoma. However, biomarkers that can be used to predict a response in these patients have not yet been found, putting patients at risk of severe side effects.
Methods: In this retrospective analysis, we investigated the association between the body mass index and ipilimumab treatment response in patients with metastatic melanoma. Patients with metastatic melanoma who received a monotherapy of up to 4 doses of ipilimumab (3 mg/kg) every 3 weeks from 2011 to 2014 in three major hospitals in Austria were included. Patients were classified into two groups: normal group (BMI<25) and overweight group (BMI≥25).
Results: 40 patients had a normal BMI, and 36 had a BMI above normal. Patients with a BMI that was above normal showed significantly higher response rates (p = 0.024, χ2), and lower likelihood of brain metastases (p = 0.012, χ2). No differences were found between both groups with respect to gender (p = 0.324, χ2), T-stage (p = 0.197, χ2), or the occurrence of side effects (p = 0.646, χ2). Patients with a BMI above normal showed a trend towards longer overall survival (p = 0.056, Log-Rank), but no difference was found regarding progression-free survival (p = 0.924, Log-Rank).
Conclusions: The BMI correlated with the response to ipilimumab treatment in a cohort of metastatic melanoma patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166940 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0204729 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!